Acadia Healthcare Company, Inc. (ACHC)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 35/100 (MEDIUM), 9.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Acadia Healthcare (ACHC) Stock May Be Below Fair Value On Sales
- Acadia Healthcare Announces Date for Third Quarter 2026 Earnings Release
- Will Acadia Healthcare (ACHC) Beat Estimates Again in Its Next Earnings Report?
- Acadia Healthcare (ACHC): Buy, Sell, or Hold Post Q2 Earnings?
- Acadia Healthcare (ACHC) Upgraded to Buy: Here's What You Should Know
- Is Acadia Healthcare (ACHC) Outperforming Other Medical Stocks This Year?
- Hospital Chains Stocks Q2 Results: Benchmarking Acadia Healthcare (NASDAQ:ACHC)
- Acadia Healthcare Jumps 100% YTD on Improving Outlook and Expansion
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Acadia Healthcare Company, Inc..
Full ACHC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.